Biotech, Cancer therapeutics, Diagnostics, Digital Health, Drug Delivery, Immunology, Medical Device, Neurosciences, Oncology, Personalised medicine, Predictive medicine, Therapeutics, molecular diagnostics, proteins, small molecules, vaccines, medical big data and analytics, population health management, molecular diagnostics, proteins, small molecules, vaccines
I am a pharmacist by background (PharmD) and studied business (ESSEC MBA), I have been involved since 2004 in early stage investment: I started with a VC fund in Paris, then I setup an advisory company for innovative SME cross-border M&A, based in New York. Since then, on top of my work as consultant for pharma blue chips I have advised start-ups on an ad hoc basis. I am involved with Future Worlds Medicine, the incubator of the University of Southampton, and supporting their start-ups with business plan reviews, partnering, fundraising, and commercial strategy planning.
Beyond these activities, I have also developed expertise from the pharma point of view, notably helping them confirm the potential of acquisition targets, and providing evidence-based advisory on growth strategy. More recently I have built the healthcare consulting practice at the Economist Intelligence Unit, notably supporting companies in building their value case for reimbursement and preparing reports on key trends for the healthcare ecosystem (Value-based Healthcare), and policy analysis (access to healthcare, medicines pricing).
I have worked on multiple projects involving oncology medicines and policies, inflammation, brain diseases, cardiovascular diseases, AI and bioinformatics and I am currently part of the Cancer Drug Development Forum, notably involved in the bio-markers and personalised medicine initiative.